EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

Investing.com -- The European Commission has granted Bristol Myers (NYSE: BMY) Squibb, the biopharmaceutical company based in ...

Aadi Bioscience, Inc.  ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, ...

Acarix, a global leader in AI and acoustics-based cardiac diagnostics, has been awarded the 2025 Digital Innovation Award with an honorable mention for Innovation in Cardiac Imaging at the Global ...

Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.

Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...